CDK7 and neuroblastoma: It was reported in doxorubicin-treated patient-derived neuroblastoma cells with a high level of MYCN that only cells in the G1 phase with repaired DNA damage may survive, while cells in other cell cycle phases eventually die [43], in line with our observations that the converged DNA damage response after high MYC-driven entry of cancer cells into the active cell cycle renders the hypersensitivity of HepG2-MYC cells to CDK7 inhibition.